1. Signaling Pathways
  2. GPCR/G Protein
  3. Free Fatty Acid Receptor
  4. FFAR1 Isoform

FFAR1

GPR40

FFAR1 (free fatty acid receptor 1, also known as GPR40) is a G protein-coupled receptor predominantly expressed in pancreatic β-cells, where it functions as a lipid sensor for medium- and long-chain free fatty acids and amplifies glucose-stimulated insulin secretion (GSIS)[1][2][3]. Mechanistically, FFAR1 activation couples primarily to Gαq/11-dependent signaling, increases intracellular Ca2+ levels, and promotes insulin exocytosis under elevated glucose conditions, thereby linking nutrient sensing to β-cell secretory function[3][4][5]. FFAR1 signaling also contributes to the regulation of incretin hormones, including glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), supporting coordinated control of glucose homeostasis and energy metabolism[4][6][7]. In disease-relevant contexts, reduced β-cell function and impaired insulin secretion are central features of type 2 diabetes, and FFAR1 has therefore emerged as a key therapeutic target for restoring glucose-dependent insulin release while minimizing hypoglycemia risk[6][8][9]. Compared with the related long-chain fatty acid receptor FFAR4 (GPR120), which is primarily associated with intestinal and macrophage functions, FFAR1 is distinguished by its predominant role in pancreatic β-cell-mediated insulin secretion[10]. For experimental applications, selective FFAR1 agonists such as fasiglifam (TAK-875) and other synthetic ligands have been widely used to investigate receptor pharmacology, β-cell signaling mechanisms, incretin regulation, and anti-diabetic therapeutic strategies[8][9][11].

FFAR1 Related Products (1):

Cat. No. Product Name Effect Purity
  • HY-153667
    MK-2305
    Agonist
    MK-2305 is an orally active GPR40 partial agonist with an EC50 of 6 nM in rats. MK-2305 mediates glucose-stimulated insulin secretion and inhibits endogenous glucose production by reducing gluconeogenesis from tricarboxylic acid (TCA) cycle substrates. MK-2305 increases plasma insulin levels under hyperglycemic and glucose-stimulated conditions, reduces fasting blood glucose, and improves glucose homeostasis. MK-2305 can be used in studies related to type 2 diabetes.